We evaluate CLS in the context of its EM pharmacy retail peers, and note the company is ideally positioned by operating in a market with moderate consolidation (which present above avergae growth opportunities), with many of its peers in this segment being unlisted. While CLS’ rating may seem high in the SA market, in the context of other pharmacy chains in its peer group, its valuation does not appear excessive.
